"目录号: HY-14720
Cell Cycle/DNA DamageAutophagy-
LY2603618 是一种有效的选择性的Chk1抑制剂，IC50为 7 nM。
Checkpoint Kinase (Chk)Autophagy
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
LY2603618 is a potent and selective inhibitor ofChk1protein kinase activity in vitro withIC50of 7 nM.
IC50& Target
IC50: 7 nM (Chk1)[1]
In Vitro
LY2603618 is a highly effective inhibitor of multiple aspects of Chk1 biology. LY2603618 is tested against a panel of 51 diverse protein kinases in vitro. With an IC50of 7 nM for Chk1, LY2603618 is approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated (PDK1, IC50=893 nM, others >1000 nM). LY2603618 effectively reduced Chk1 autophosphorylation with an EC50of 430 nM. Inhibition of Chk1 by LY2603618 also effectively abrogated the G2/M DNA damage checkpoint in cells treated with DNA damaging agents. Treatment of cells with LY2603618 produced a cellular phenotype similar to that reported for depletion of Chk1 by RNAi. Inhibition of intracellular Chk1 by LY2603618 results in impaired DNA synthesis, elevated H2A.X phosphorylation indicative of DNA damage and premature entry into mitosis[1]. Treatments of the SK-N-BE(2) cells with variable concentrations of LY2603618 results in dose-dependent inhibition of cell growth determined by MTT assays with an IC50of 10.81 μM[1].
In Vivo
Mice bearing Calu-6 xenografts are treated with 150 mg/kg (IP) Gemcitabine and a single simultaneous 200 mg/kg oral dose of LY2603618. 200 mg/kg of LY2603618 is sufficient to inhibit 85 % of Chk1 autophosphorylation in vivo at 2 h. LY2603618 effectively reduces Gemcitabine-induced phosphorylation on Tlk serine 695 as well, supporting the cited report with a selective chemical inhibitor of Chk1[1].
Clinical Trial
NCT01358968
Eli Lilly and Company
Cancer
June 2011
Phase 1
NCT01341457
Eli Lilly and Company
Solid Tumors
May 2011
Phase 1
NCT01296568
Eli Lilly and Company
Advanced Cancer
February 2011
Phase 1
NCT00415636
Eli Lilly and Company
Cancer
December 2006
Phase 1
NCT00839332
Eli Lilly and Company
Pancreatic Neoplasms
March 2009
Phase 1-Phase 2
NCT01139775
Eli Lilly and Company
Non Small Cell Lung Cancer
February 2011
Phase 1-Phase 2
NCT00988858
Eli Lilly and Company
Non Small Cell Lung Cancer
November 2009
Phase 2
View MoreCollapse
References
[1].King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
[2].Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662.